MAP3K20

Across TCGA pan-cancer cohorts, MAP3K20 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAP3K20 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAP3K20 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MAP3K20 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where MAP3K20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.228	0.979	.003	21	view →
GBM	DFS	Median	All	0.272	0.463	.012	11	view →
PDAC	OS	Median	IV	0.836	0.491	.024	6	view →
HNSC	OS	Median	IV	0.831	0.599	.012	4	view →
LUAD	OS	Median	All	0.828	0.661	.034	3	view →
LSCC	OS	Median	All	0.793	1.000	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAP3K20–CCRCC (OS)

Open the CCRCC breakdown →